OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing
OvaScience Reports Second Quarter 2018 Financial Results and Provides Strategic Alternatives Update
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update
OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results
OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)